Bisphosphonate drugs reduce the risk of bone complications when used in patients whose cancer has spread to the bone, according to a new study in the BMJ.
Researchers reviewed over 30 studies examining the effect of bisphosphonates - a group of drugs commonly used to treat osteoporosis - on complications of secondary bone cancer. Cancers that commonly spread to the bone include breast cancer, prostate cancer and multiple myeloma.
They found that patients given bisphosphonate drugs were much less likely to suffer from fractures, or need orthopaedic surgery or radiotherapy. The researchers also found that patients given bisphosphonate drugs remained free of bone complications for a significantly longer period of time compared to those who did not receive the drug. However, patients given bisphosphonates did not survive longer.
Emma Dickinson | alfa
Investigators may unlock mystery of how staph cells dodge the body's immune system
22.09.2017 | Cedars-Sinai Medical Center
Monitoring the heart's mitochondria to predict cardiac arrest?
21.09.2017 | Boston Children's Hospital
A warming planet
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
22.09.2017 | Life Sciences
22.09.2017 | Medical Engineering
22.09.2017 | Physics and Astronomy